Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is highly promising but requires robust T-cell expansion and engraftment. A T-cell defect in chronic lymphocytic leukemia (CLL) due to disease and/or therapy impairs ex vivo expansion and response to CAR T cells. To evaluate the effect of ibru...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood
Egile Nagusiak: Fraietta, Joseph A., Beckwith, Kyle A., Patel, Prachi R., Ruella, Marco, Zheng, Zhaohui, Barrett, David M., Lacey, Simon F., Melenhorst, Jan Joseph, McGettigan, Shannon E., Cook, Danielle R., Zhang, Changfeng, Xu, Jun, Do, Priscilla, Hulitt, Jessica, Kudchodkar, Sagar B., Cogdill, Alexandria P., Gill, Saar, Porter, David L., Woyach, Jennifer A., Long, Meixiao, Johnson, Amy J., Maddocks, Kami, Muthusamy, Natarajan, Levine, Bruce L., June, Carl H., Byrd, John C., Maus, Marcela V.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2016
Gaiak:
Immunobiology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4778162/
https://ncbi.nlm.nih.gov/pubmed/26813675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-11-679134
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak